Cybin Reiterates Q4 Phase III MDD Readout; WAIT Intact

What happened

Cybin (now Helus Pharma, HELP) confirmed at an investor conference that results from the first Phase III trial of its adjunctive major depressive disorder candidate are expected later this quarter, aligning with previously guided Q4 2026 timing. The trial, likely APPROACH, is the core value driver for the company, with a binary outcome that will determine whether the lead program can support an NDA filing. The news adds no new information beyond prior guidance, but serves as a reminder of the near-term catalyst and the concentrated risk around a single readout. With a ~$413M market cap and ~$225M net cash, the market is pricing in a range of outcomes, but the probability of failure remains meaningful given historical Phase III attrition in depression. The company's burn rate of ~$35M/quarter leaves limited margin for error; a disappointing result would sharply curtail the runway and likely trigger significant dilution.

Implication

Investors should await the APPROACH data before adding exposure; a positive outcome could justify a re-rating, but the current price embeds non-trivial optimism despite the lack of de-risking. If the trial fails, the stock could fall toward the bear-case implied value of $4 or lower, while success might push it toward $14, but the probability-weighted expected value is close to the base case of $9, offering limited upside from $7.85. Even with positive data, the company will likely need additional capital to fund ongoing Phase 3 and potential commercialization, keeping dilution risk elevated. The lack of updated enrollment metrics for EMBRACE and the CEO transition add execution uncertainty that is not fully captured by the headline. We prefer to see the data and subsequent management commentary on spending before reassessing the rating.

Thesis delta

The thesis remains unchanged: Cybin is a high-risk, high-reward late-stage neuropsychiatry play awaiting binary Phase III data. The news is a reiteration of timing, not a fundamental shift. Our WAIT rating and scenarios stand as the risk/reward is balanced at current levels.